Donald Quick is an Oncology physician affiliated with Texas Tech University. OpenAlex indexes 78 publications with 1,383 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4101 22nd Place
Lubbock, TX 79410
Telephone
806-725-8000Provider last certified this registry record 26 Feb 2020.
Industry payments
25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20255 payments
- Genentech USA, Inc.Program year20254 payments
- PFIZER INC.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
39.5%Kinase inhibitor17.1%Brukinsa24%Imbruvica15%Jakafi14%Imatinib Mesylate14%Tasigna13%Sprycel9%Iclusig5%Calquence5%Part D<11 patientsThalidomide Analog12%Lenalidomide62%Pomalyst20%Revlimid18%Part D<11 patients+ 3 more classes in this area
Blood & clotting
22.3%Factor Xa inhibitor18.2%Eliquis85%Xarelto15%Part D≥41 patientsVitamin K antagonist1.8%Warfarin Sodium100%Part D≥14 patients+ 2 more classes in this area
Dermatology
12.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor12.9%Acyclovir100%Part D≥43 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014
Clinical Lymphoma Myeloma & Leukemia
2024 - Pembrolizumab Induced Recall Dermatitis Occurring 5 Years After Radiotherapy
Reports — Medical Cases Images and Videos
2024 - Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies
Cancer Chemotherapy and Pharmacology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Debabrata Mukherjee, MD
Texas Tech University
Kenneth Nugent, MD
Texas Tech University
Javier Corral, MD
Texas Tech University
Marc Zuckerman, MD
Texas Tech University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”